Xilio Therapeutics(XLO)
$7.51-0.12 (-1.57%)
XLO
Xilio Therapeutics financials statements
$7.51
At close:-0.12 (-1.57%)
Want to see XLO full AI Analyst Report?
Xilio Therapeutics (XLO) Ratios
222 Followers
Xilio Therapeutics Ratios
XLO's free cash flow for Q3 2026 was $-13.85M. For the 2026 fiscal year, XLO's free cash flow was decreased by $-58.00K and operating cash flow was $-13.79M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.58 | 2.21 | 3.02 | 5.89 | 15.85 |
| Quick Ratio | 2.58 | 2.21 | 3.02 | 5.89 | 15.85 |
| Cash Ratio | 2.44 | 2.03 | 2.80 | 5.70 | 15.50 |
| Solvency Ratio | -0.28 | -1.06 | -3.09 | -2.58 | -2.05 |
| Operating Cash Flow Ratio | -0.09 | -0.67 | -4.30 | -3.59 | -6.32 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | -20.70 | -11.36 | -91.45 |
| Net Current Asset Value | $ 25.61M | $ 6.76M | $ 24.03M | $ 90.98M | $ 166.35M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.04 | 0.11 | 0.19 | 0.14 | 0.09 |
| Debt-to-Equity Ratio | 0.20 | 0.46 | 0.31 | 0.19 | 0.11 |
| Debt-to-Capital Ratio | 0.16 | 0.32 | 0.24 | 0.16 | 0.10 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.03 | 0.05 |
| Financial Leverage Ratio | 4.39 | 4.04 | 1.65 | 1.32 | 1.20 |
| Debt Service Coverage Ratio | 0.00 | -580.01 | -23.30 | -13.09 | -49.70 |
| Interest Coverage Ratio | 0.00 | -605.82 | 0.00 | 0.00 | -125.07 |
| Debt to Market Cap | 0.00 | 0.00 | 0.22 | 0.13 | 0.02 |
| Interest Debt Per Share | 0.83 | 2.16 | 0.42 | 0.73 | 0.78 |
| Net Debt to EBITDA | 3.90 | 0.81 | 0.43 | 1.15 | 2.41 |
| Profitability Margins | |||||
| Gross Profit Margin | 96.48% | 100.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | -80.05% | -940.18% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | -76.53% | -914.27% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | -95.92% | -954.95% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | -80.05% | -918.05% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | -80.05% | -918.05% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | -80.05% | -918.05% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 83.45% | 96.14% | 96.55% | 98.96% | 101.01% |
| Return on Assets (ROA) | -22.65% | -81.94% | -125.40% | -63.39% | -34.21% |
| Return on Equity (ROE) | -99.33% | -330.95% | -207.47% | -83.51% | -40.88% |
| Return on Capital Employed (ROCE) | -42.66% | -138.27% | -175.97% | -75.52% | -35.94% |
| Return on Invested Capital (ROIC) | -42.09% | -134.62% | -163.89% | -70.96% | -35.79% |
| Return on Tangible Assets | -22.65% | -81.94% | -125.40% | -63.39% | -34.21% |
| Earnings Yield | -46.78% | -113.97% | -505.22% | -119.73% | -17.32% |
| Efficiency Ratios | |||||
| Receivables Turnover | 8.75 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.49 | 0.00 | 0.00 | 0.00 | 0.48 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 5.57 | 0.70 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.28 | 0.09 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.72 | 0.19 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -708.67 | 0.00 | 0.00 | 0.00 | -765.55 |
| Days of Sales Outstanding | 41.70 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 750.37 | 0.00 | 0.00 | 0.00 | 765.55 |
| Operating Cycle | 41.70 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.60 | -4.81 | -2.50 | -2.76 | -2.95 |
| Free Cash Flow Per Share | -0.66 | -4.82 | -2.51 | -2.83 | -2.99 |
| Dividend Paid and CapEx Coverage Ratio | -9.64 | -510.50 | -141.19 | -40.56 | -73.41 |
| Capital Expenditure Coverage Ratio | -9.64 | -510.50 | -141.19 | -40.56 | -73.41 |
| Operating Cash Flow Coverage Ratio | -0.72 | -2.26 | -5.99 | -3.80 | -3.89 |
| Operating Cash Flow to Sales Ratio | -0.11 | -2.90 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -7.36% | -36.03% | -456.97% | -105.30% | -18.70% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -2.14 | -0.88 | -0.20 | -0.84 | -5.77 |
| Price-to-Sales (P/S) Ratio | 1.71 | 8.06 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 2.12 | 2.90 | 0.41 | 0.70 | 2.36 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -13.59 | -2.78 | -0.22 | -0.95 | -5.35 |
| Price-to-Operating Cash Flow Ratio | -15.00 | -2.78 | -0.22 | -0.97 | -5.42 |
| Price-to-Earnings Growth (PEG) Ratio | 0.03 | 0.01 | 0.02 | -0.05 | -0.16 |
| Enterprise Value Multiple | 1.66 | -0.07 | 0.23 | 0.31 | -3.53 |
| Enterprise Value | -55.68M | 3.95M | -18.12M | -26.76M | 260.42M |
| EV to EBITDA | 1.66 | -0.07 | 0.23 | 0.31 | -3.53 |
| EV to Sales | -1.27 | 0.62 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | 10.11 | -0.21 | 0.26 | 0.34 | -3.18 |
| EV to Operating Cash Flow | 11.15 | -0.22 | 0.26 | 0.35 | -3.22 |
| Tangible Book Value Per Share | 4.22 | 4.60 | 1.34 | 3.86 | 6.78 |
| Shareholders’ Equity Per Share | 4.22 | 4.60 | 1.34 | 3.86 | 6.78 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 5.24 | 1.66 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -4.19 | -15.24 | -2.78 | -3.22 | -2.77 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 0.98 | 0.97 | 0.99 | 1.01 |
| Research & Development to Revenue | 1.28 | 6.50 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.68 | 3.91 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.16 | 1.01 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.14 | 0.32 | 0.90 | 0.86 | 1.07 |
Currency in USD

